Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Bernstein Senior Analyst, US Biopharmaceuticals Courtney ... industry and painted the order as a blow against drugmakers. Eli Lilly (NYSE:LLY) recently announced the impressive results of its ...

Eli Lilly's stock ... BMO Capital Markets analyst Evan Seigerman said, per Reuters. Additionally, no liver-related safety signal was observed in the trial, Lilly said. Lilly's new pill can be ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that ...